Cleo Diagnostics (ASX:COV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cleo Diagnostics (ASX:COV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
CLEO Receives First Batch of Commercial Test Kits
Cleo Diagnostics begins Analytical Validation of ovarian cancer test kits ahead of FDA submission
Change of Director's Interest Notice x 4
Cleansing Notice
Application for quotation of securities - COV
Notification of cessation of securities - COV
Change in Director's Interest Notice
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Cleo Diagnostics reports increased loss and advances ovarian cancer test development with US trial completion and FDA progress
Quarterly activities and cashflow report
Cleo Diagnostics advances FDA submission and U.S. reimbursement pathway with A$6.2m cash
CLEO Enters Analytical Validation Phase
Cleo Diagnostics Commences Analytical Validation Phase Ahead of FDA Submission
Change in Director's Interest Notice